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RNA-mediated epigenetic gene silencing of 
the D4Z4 repeats and the DUX4 gene 
embedded in the repeat. 
 




Facioscapulohumeral dystrophy (FSHD) is a neuromuscular disorder characterized by progressive 
weakness of skeletal muscle, most noticeably in muscles of the face (facio), back (scapula) and 
upper arms (humeral), and is estimated to affect almost one million people worldwide. FSHD is 
thought to be caused by mis-expression of DUX4, a homeobox transcription factor that is normally 
only expressed in testes but is misexpressed in FSHD skeletal muscle cells. The DUX4 gene resides 
within a macrosatellite repeat known as D4Z4, and the size of the D4Z4 array correlates with FSHD 
severity. For example, unaffected individuals have between 11 and 100 units of the array, whereas 
contraction of the array to between 1 and 10 units is linked to FSHD. However, the epigenetic 
mechanisms that repress DUX4 expression in normal muscle cells remain to be completely 
elucidated. A new Fred Hutch study by the Tapscott Laboratory (Human Biology and Clinical 
Research Divisions), led by Drs. Jong-Won Lim, Laurie Snider and Gala Filippova, and published in 
Human Molecular Genetics, showed that the endogenous RNAi pathway is required to silence the 
D4Z4 repeat array and DUX4 expression and that exogenous small interfering RNAs (siRNAs) that 
mimic endogenous D4Z4 small RNAs enhance epigenetic silencing of the D4Z4 array. "Our work 
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suggested a potential mechanism by which the D4Z4 repeat (and the DUX4 gene imbedded in the 
repeat) is silenced by small RNAs generated from D4Z4 in the nonpathogenic condition. We expect 
therapeutic targeting strategies based on this mechanism would be effective for epigenetic silencing 
of DUX4, the FSHD causing gene, in FSHD condition," said Dr. Lim. 
The authors had previously identified bidirectional transcripts and small RNAs throughout the D4Z4 
region. To determine if such RNAs could modulate DUX4 expression, the researchers synthesized 
siRNAs that targeted not only the coding region of DUX4, but also the upstream non-coding region, 
often referred to as the promoter. Remarkably, the promoter siRNAs could suppress DUX4 
expression as potently as the coding region siRNAs, albeit with delayed kinetics. This delayed effect 
is consistent with a model in which promoter siRNAs repress DUX4 transcription, whereas coding 
region siRNAs degrade the DUX4 mRNA directly. Because siRNA-dependent transcriptional 
silencing is known to involve Argonaute (AGO) proteins and dimethylation of Histone H3 on lysine 9 
(H3K9me2), the authors examined both AGO recruitment and H3K9 methylation status by chromatin 
immunoprecipitation. This analysis revealed that promoter siRNAs increase the amount of AGO2 
and H3K9me2 at the D4Z4 repeats. 
To further probe the role of the RNAi pathway in the epigenetic silencing of DUX4, the authors 
knocked down DICER1, AGO1 and AGO2 in control myoblasts derived from unaffected individuals 
that had 13 D4Z4 repeats, which is in the low range of the non-FSHD population. Strikingly, the 
authors observed de-repression of both DUX4 and DUX4 target genes in cells that contained 13 
D4Z4 units. In contrast, knockdown of RNAi components in control cells obtained from unaffected 
individuals that contained 74 D4Z4 repeats did not result in DUX4 de-repression. Furthermore, 
knocking down AGO2 prevented promoter siRNAs from suppressing DUX4 expression in FSHD 
cells. Importantly, targeting non-coding RNAs upstream of DUX4 for degradation was not sufficient 
to de-repress DUX4, consistent with the proposed RNAi mechanism. 
"Although still not widely accepted, this evolutionarily conserved RNA-mediated silencing 
mechanism clearly plays an important role in keeping repeats and genes imbedded in the repeats 
under control in both normal development and disease,such as FSHD" said Dr. Filippova. Overall, 
this study demonstrated the role of the endogenous RNAi pathway in epigenetic repression of 
DUX4, and suggests that enhancing the activity of this pathway with exogenous siRNAs could be a 
valid therapeutic approach to silence DUX4 in FSHD. 
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siRNA suggests mechanisms and therapies for FSHD. Hum Mol Genet. pii: ddv206. DOI: 
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